Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Paul DePietro"'
Autor:
Mary K. Nesline, Vivek Subbiah, Rebecca A. Previs, Kyle C. Strickland, Heidi Ko, Paul DePietro, Michael D. Biorn, Maureen Cooper, Nini Wu, Jeffrey Conroy, Sarabjot Pabla, Shengle Zhang, Zachary D. Wallen, Pratheesh Sathyan, Kamal Saini, Marcia Eisenberg, Brian Caveney, Eric A. Severson, Shakti Ramkissoon
Publikováno v:
Oncology and Therapy, Vol 12, Iss 2, Pp 329-343 (2024)
Abstract Introduction Tissue-based broad molecular profiling of guideline-recommended biomarkers is advised for the therapeutic management of patients with non-small cell lung cancer (NSCLC). However, practice variation can affect whether all indicat
Externí odkaz:
https://doaj.org/article/faa519bba6084d7cb86ca6ab28c54740
Autor:
R. J. Seager, Maria-Fernanda Senosain, Erik Van Roey, Shuang Gao, Paul DePietro, Mary K. Nesline, Durga Prasad Dash, Shengle Zhang, Heidi Ko, Stephanie B. Hastings, Kyle C. Strickland, Rebecca A. Previs, Taylor J. Jensen, Marcia Eisenberg, Brian J. Caveney, Eric A. Severson, Shakti Ramkissoon, Jeffrey M. Conroy, Sarabjot Pabla
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Cancer-testis antigens (CTAs) are tumor antigens that are normally expressed in the testes but are aberrantly expressed in several cancers. CTA overexpression drives the metastasis and progression of lung cancer, and is associated
Externí odkaz:
https://doaj.org/article/c349be77b0f14a3eaaf56d8588b10579
Autor:
Yu Fujiwara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K. Nesline, Jeffrey M. Conroy, Paul DePietro, Sarabjot Pabla, Scott M. Lippman, Razelle Kurzrock
Publikováno v:
iScience, Vol 27, Iss 4, Pp 109632- (2024)
Summary: Indoleamine 2,3-dioxygenase 1 (IDO1), which catabolizes tryptophan, is a potential target to unlock the immunosuppressive tumor microenvironment. Correlations between IDO1 and immune checkpoint inhibitor (ICI) efficacy remain unclear. Herein
Externí odkaz:
https://doaj.org/article/9df1b09acc8f49f69d386a55f32c1121
Autor:
Hirotaka Miyashita, Razelle Kurzrock, Nicholas J. Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Jeffrey M. Conroy, Paul DePietro, Eitan Rubin, Jason K. Sicklick, Shumei Kato
Publikováno v:
npj Genomic Medicine, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneit
Externí odkaz:
https://doaj.org/article/9b9d07a8e8b84b69aa3ad5d3d41c13e8
Autor:
Jacob J. Adashek, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M. Conroy, Paul DePietro, Scott Lippman, Razelle Kurzrock
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13155-13166 (2023)
Abstract Background Lymphocyte activation gene 3 (LAG‐3) or CD223 is a transmembrane protein that serves as an immune checkpoint which attenuates T‐cell activation. Many clinical trials of LAG‐3 inhibitors have had modest effects, but recent da
Externí odkaz:
https://doaj.org/article/cfe72fc33e194e9395740e5950d4b95c
Autor:
Nithya Krishnamurthy, Daisuke Nishizaki, Scott M. Lippman, Hirotaka Miyashita, Mary K. Nesline, Sarabjot Pabla, Jeffrey M. Conroy, Paul DePietro, Shumei Kato, Razelle Kurzrock
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: CTLA-4 impedes the immune system’s antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents – ipilimumab and tremelimumab – both used together with anti-PD-1/PD-L1 agents. Objective: To assess the p
Externí odkaz:
https://doaj.org/article/302a5bad7fa94428a127ac93ea60fd33
Autor:
Jungah Lim, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M. Conroy, Paul DePietro, Scott M. Lippman, Shumei Kato
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Background T‐cell immunoglobulin and mucin domain‐containing protein 3 (TIM‐3), an immune checkpoint receptor, dampens immune function. TIM‐3 antagonists have entered the clinic. Methods We analyzed TIM‐3 transcriptomic expression
Externí odkaz:
https://doaj.org/article/faba3e63388e469f81fc01e32dc0a947
Autor:
Razelle Kurzrock, Sarabjot Pabla, Shumei Kato, Nithya Krishnamurthy, Paul DePietro, Mary K Nesline, Jeffrey M Conroy, Daisuke Nishizaki, Scott M Lippman, Hirotaka Miyashita
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8be7f0786b434fde8b030d0afedc722a
Autor:
Aditya Shreenivas, Daisuke Nishizaki, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M. Conroy, Paul DePietro, Shumei Kato, Razelle Kurzrock
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 9, p 4742 (2024)
ADORA2A (adenosine A2a receptor) and ADORA2B propagate immunoregulatory signals, including restricting both innate and adaptive immunity, though recent data also suggest a tumor suppressor effect in certain settings. We evaluated the RNA expression f
Externí odkaz:
https://doaj.org/article/d26f166fe9ee486db3018a55976a13a9
Autor:
Mary K. Nesline, Rebecca A. Previs, Grace K. Dy, Lei Deng, Yong Hee Lee, Paul DePietro, Shengle Zhang, Nathan Meyers, Eric Severson, Shakti Ramkissoon, Sarabjot Pabla, Jeffrey M. Conroy
Publikováno v:
Cancers, Vol 15, Iss 19, p 4789 (2023)
Programmed cell death ligand (PD-L1) expression by immunohistochemistry (IHC) lacks sensitivity for pembrolizumab immunotherapy selection in non-small cell lung cancer (NSCLC), particularly for tumors with low expression. We retrospectively evaluated
Externí odkaz:
https://doaj.org/article/760b464df546479b8e7b006ac50ec43b